Breast Cancer DNA Test comprehensive

The BRCA1, BRCA2, and HRR Genes Panel by DrOmics Labs is a cutting-edge genetic test aimed at transforming cancer risk assessment. While mutations in the BRCA1 and BRCA2 genes are well-known drivers of hereditary cancers, other genes in the Homologous Recombination Repair (HRR) pathway significantly impact cancer susceptibility.
This panel comprehensively analyzes mutations in BRCA1, BRCA2, and other HRR pathway genes, providing actionable insights into cancer risks. By pinpointing genetic defects in DNA repair mechanisms, this test empowers individuals to take informed steps toward cancer prevention, early detection, and personalized treatment strategies.
DrOmics Labs’ BRCA1/BRCA2 with HRR Genes Panel is tailored for personalized healthcare, equipping individuals with the knowledge to manage their cancer risks effectively.

Looking for more? We offer competitive pricing—contact us for the best deals!

Quantity

Breast Cancer DNA Test comprehensive

The BRCA1, BRCA2, and HRR Genes Panel by DrOmics Labs is a cutting-edge genetic test aimed at transforming cancer risk assessment. While mutations in the BRCA1 and BRCA2 genes are well-known drivers of hereditary cancers, other genes in the Homologous Recombination Repair (HRR) pathway significantly impact cancer susceptibility.

This panel comprehensively analyzes mutations in BRCA1, BRCA2, and other HRR pathway genes, providing actionable insights into cancer risks. By pinpointing genetic defects in DNA repair mechanisms, this test empowers individuals to take informed steps toward cancer prevention, early detection, and personalized treatment strategies.

DrOmics Labs’ BRCA1/BRCA2 with HRR Genes Panel is tailored for personalized healthcare, equipping individuals with the knowledge to manage their cancer risks effectively.

1. Who Should Take the BRCAOmics Test?

The BRCAOmics Test is highly recommended for individuals who:

  • Have a Family History of Cancer: If immediate family members have been diagnosed with breast, ovarian, pancreatic, or prostate cancer, understanding inherited risks can guide preventive actions.
  • Are Cancer Survivors: Those diagnosed with cancer may benefit from understanding if a BRCA mutation contributed to their condition, which could guide further treatment options or assess risks for other cancers.
  • Want Comprehensive Cancer Risk Insights: This test not only screens for breast cancer risk but also evaluates risks for other cancers associated with BRCA mutations.
  • For Women Seeking Early Detection: If you’re concerned about your breast cancer risk, this test allows for early detection of BRCA gene mutations, enabling you to begin early screenings or preventative measures, such as regular mammograms or prophylactic surgeries.
  • Have Relatives with BRCA Mutations: For families where a known mutation exists, this test can determine if others carry the same risk.
2. Why Is This Test Important?

The BRCAOmics Test is a cornerstone of preventive healthcare for individuals at risk of BRCA-related cancers. Here’s why it matters:

  • Early Detection Saves Lives: Identifying mutations in BRCA1 and BRCA2 genes before cancer develops enables individuals to take timely preventive actions, including enhanced surveillance or risk-reducing measures. (5)
  • Comprehensive Cancer Risk Assessment: This test detects mutations not only in BRCA1 and BRCA2 but also in multiple HRR pathway genes like PALB2, ATM, CHEK2, RAD51, etc., which are linked to cancer susceptibility. (6)
  • Personalized Prevention Strategies: Tailored recommendations based on genetic findings help reduce cancer risk through preventive surgeries, lifestyle changes, or targeted screenings. (7)
  • Guides Treatment Plans: For those diagnosed with cancer, knowing their genetic makeup allows for targeted treatments like PARP inhibitors for BRCA mutation-related cancer s.(8)
  • Family Health Awareness: Test results can also guide relatives in understanding the genetic risks. (9)
  • Support Through Genetic Counseling: Our test includes access to expert counselors to help interpret results and plan the next steps confidently. (10)

Genetic Insight

General Population Estimates: Mutations in BRCA1 (0.7%) and BRCA2 (1.3%) were identified in a population-based study of 1,220 breast cancer cases, with penetrance by age 80 estimated at 48% and 74%, respectively. Combined ovarian cancer risk was 22%, and BRCA mutations accounted for 17% of familial breast cancer risk. These findings suggest that BRCA mutations are rare and contribute to a small fraction of breast cancer cases(1)(3)

Breast Cancer Patients: Among women diagnosed with breast cancer:

A study reported that 5.9% of women diagnosed before age 36 carried BRCA mutations, with 3.5% in BRCA1 and 2.4% in BRCA2. (2)

In the Indian cohort, the prevalence of pathogenic BRCA mutations was found to be 16.6% among unselected consecutive breast cancer patients, which is notably higher than some previous estimates. (1)

Ovarian Cancer Patients: In a cohort of ovarian cancer patients, 29.8% were identified as carriers of BRCA mutations, with a predominance of BRCA1 mutations (75.8%) compared to BRCA2 (24.2%). (4)

Prostate Cancer:

In men with metastatic castration-resistant prostate cancer (mCRPC), the prevalence of HRR gene mutations is reported to be between 11% to 33%. The most commonly mutated genes in this context include BRCA2, ATM, and CDK12.(11)

A study indicated that up to one-third of patients with mCRPC harbor HRR mutations, with a significant proportion having non-BRCA1/2 HRR mutations. (12)

3. DrOmics BRCAOmics Test for Genetic Cancer Risk

DrOmics Labs sets the gold standard in genetic testing for BRCA gene mutations with its BRCAOmics Test:

  • Comprehensive Risk Analysis: Covers a wide spectrum of cancers, including breast cancer genetic testing, ovarian cancer screening, and prostate cancer risk assessment.
  • Cutting-Edge Technology: Leveraging advanced sequencing methods for precise and reliable results.
  • Integrated Counseling Services: Results are supported by genetic counseling for cancer, helping individuals understand their genetic risks and plan proactive measures.
  • Customized Preventive Care: Tailored recommendations for preventive surgeries, lifestyle adjustments, and enhanced surveillance protocols.
  • Scientific and Clinical Validity: Developed in adherence to globally recognized databases like BRCAIndica, gnomADand, and ClinVar, ensuring reliability and trustworthiness.
4. What Makes DrOmics’ BRCAOmics Test Stand Out?

DrOmics Labs is at the forefront of genetic testing, offering unique benefits that make its BRCAOmics Test exceptional:

  • Comprehensive Risk Analysis: Covers a wide spectrum of cancers, including breast cancer genetic testing, ovarian cancer screening, and prostate cancer risk assessment.
  • Region-Specific Genetic Data: Tailored for Indian and South Asian populations, DrOmics Labs focuses on genetic mutations specific to these groups, filling the gap in global databases and ensuring more accurate risk assessments for breast and ovarian cancers.
  • Enhanced Mutation Detection: Identifies rare and novel mutations prevalent in South Asians, improving early detection and sensitivity of tests by highlighting mutation hotspots not captured in global databases like gnomAD, ClinVar, and BRCAIndica.
  • Robust Data for Clinical Use: DrOmics Labs provides clinically relevant insights powered by region-specific, up-to-date data, enabling better clinical decision-making for hereditary cancer risk in South Asian populations.
  • Comprehensive Genomic Risk Assessment: Offers complete coverage of all mutation types (point mutations, indels, deletions, duplications) to ensure a thorough assessment of cancer risks, including rare variants unique to the South Asian context.
  • Advanced Risk Profiling: Provides an in-depth evaluation of mutations across the HRR genes (such as PALB2, ATM, CHEK2, RAD51, and BARD1) and their links to defective DNA repair, enhancing your understanding of cancer risks.
  • Cancer Risk Assessment and Reporting: Detailed reports adhering to ACMG (American College of Medical Genetics) guidelines. Insights into pathogenic, likely pathogenic, and VUS variants for clinical decision-making.
  • State-of-the-Art Platforms: Combines SNP Microarray (5,682 SNPs) with Whole Exome Sequencing (WES, 4,523 SNPs in exonic regions)
5. How Does This Work?

The process of undergoing the BRCAOmics Test is simple, efficient, and designed with patient comfort in mind:

  1. Sample Collection: A non-invasive saliva or cheek swab sample is collected.
  2. State-of-the-Art Lab Analysis: The sample undergoes rigorous analysis to detect mutations in the BRCA1 and BRCA2 genes.
  3. Detailed Reporting: You receive a comprehensive report detailing any genetic mutations, associated cancer risks, and recommended preventive or treatment measures.
  4. Expert Consultation: Genetic counselors review your results with you, offering personalized guidance and action plans.

Reviews

There are no reviews yet.

Be the first to review “Breast Cancer DNA Test comprehensive”

Your email address will not be published. Required fields are marked *

Breast Cancer DNA Test comprehensive

Bitbucket
Call Now Button